2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.
This randomized study compared frontline nivolumab (Opdivo) with chemotherapy in patients with lung cancer that had PD-L1 positivity.
Although the trial was negative, tumor mutation burden was found to be a good predictor of who was likely to derive benefit from immunotherapy as opposed to chemotherapy, says Heymach.
Related Content: